New hope for hard-to-treat leukemia: experimental combo enters early testing
NCT ID NCT07303660
First seen Jan 11, 2026 · Last updated May 13, 2026 · Updated 24 times
Summary
This early-phase study tests a new drug called lonitoclax combined with azacitidine in 66 adults with acute myeloid leukemia (AML) that has returned or not improved after prior therapy. The main goal is to find the safest dose and see if the combination can shrink or control the cancer. Participants must have a low white blood cell count at the start and be able to give informed consent.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.